Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value

A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.

ImmunoACT’s success in delivering India’s first indigenously developed CAR-T cell therapy has drawn renewed attention to the potential for cutting-edge R&D advances in the country.

Key Takeaways

  • India’s success in CAR-T therapies depicts effective collaboration between ecosystem stakeholders

More from R&D

More from Scrip